Process and Scale-up

--:--
In general, the work done in a laboratory cannot be simply multiplied up to an industrial scale because of the inevitable consequences of increased scale, such as a decrease in surface area and volume ratio. This may seem insignificant in the lab (for example a bit of foam), but it may be significant at industrial scale (the bit of foam has its own structure and impedes the addition of other materials).

https://www.creative-biolabs.com/drug-discovery/therapeutics/process-and-scale-up.htm
30 Dec 2022 English United States Life Sciences · Life Sciences

Other recent episodes

ADCP Assays

Antibody-dependent cellular phagocytosis (ADCP) is one crucial MOA of many antibody therapies. It is defined as a highly regulated process by which antibodies eliminate bound targets via connecting its Fc domain to specific receptors on phagocytic cells, and eliciting phagocytosis.
6 Mar 13 min

In Vivo ADME

Preclinical in vivo ADME study is an important component of the drug development process which is designed to investigate the absorption, distribution, metabolism, and excretion of test articles. In addition to supporting drug discovery, lead candidate selection, preclinical testing, and clinical programs, in vivo ADME study also plays a key…
6 Mar 13 min

ADCC Assays

There are plenty of sophisticated mechanisms in the human immune system to identify and eliminate unwanted cells (e.g., viral infection and tumor). Amongst these, antibody-dependent cellular cytotoxicity, namely ADCC, plays a crucial role.
6 Mar 13 min

6-OHDA Unilateral Lesion Rat Model of Parkinson's Disease

6-OHDA is a selective catecholaminergic neurotoxin that is used, mainly, to generate lesions in the nigrostriatal dopamine (DA) neurons in rats. This neurotoxin for PD model was first introduced in 1968 by Ungerstedt when he noticed that a unilateral application of 6-OHDA into the nucleus caudatus putamen or the substantia…
6 Mar 13 min

6-OHDA Unilateral Lesion Rat Model of Parkinson's Disease

Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the global population over 65 years of age. Robust, well-validated pre-clinical models of PD are valuable tools for understanding the biology and possible treatment of this complex disease.
6 Mar 13 min